Table 2.
Ca.1 | Ca.2 | Ca.3 | Ca.4 | Ca.5 | Ca.6 | Ca.7 | Ca.8 | Ca.9 | |
---|---|---|---|---|---|---|---|---|---|
LM | |||||||||
%globally sclerotic glomeruli | 0/30 | 1/23 | 0/18 | 0/33 | 0/24 | 1/18 | 1/38 | 0/20 | 1/31 |
%segmentally sclerotic glomeruli | 0/30 | 0/23 | 0/18 | 0/33 | 0/24 | 0/18 | 1/38 | 0/20 | 1/31 |
Mesangial cell proliferation | + | + | + | + | + | + | + | - | + |
Mesangial matrix hyperplasia | + | + | + | + | + | + | + | + | + |
Thickening of the capillary walls | ++ | + | ++ | ++ | ++ | ++ | ++ | ++ | ++ |
Interstitial inflammatory | + | + | + | + | ± | - | + | - | - |
Focal tubular atrophy | + | + | + | + | - | - | - | - | + |
IF | |||||||||
IgG | +++ | ++ | +++ | +++ | +++ | ++ | ++ | ++ | +++ |
IgA | ++(f) | + | ++ | +(f) | ++ | ++ | ++ | ++ | ++ |
IgG1 | +/++ | ± | ++ | - | ++ | + | - | + | - |
IgG2 | ± | + | - | - | ± | - | ± | ± | + |
IgG3 | ± | +/++ | - | + | + | - | ± | ± | - |
IgG4 | ++ | ++ | ++++ | ++ | +++ | ++ | ++ | ++ | ++ |
PLA2R | + | + | + | ++ | +/++ | + | + | + | + |
C3 | +/++ | + | ++ | +/++ | +++ | + | +/++ | + | ++ |
EM | |||||||||
Subepithelium EDD | ++ | ++ | ++ | ++ | ++ | ++ | +++ | ++ | ++ |
Mesangial area EDD | ++ | + | + | + | + | + | ++ | + | + |
Extensive processes effacement | ++ | ++ | ++ | ++ | +/++ | + | ++ | ++ | ++ |
Mesangial matrix hyperplasia | + | - | + | + | - | - | + | - | + |
Note: Ca. case, f focal